Clinical Trial Update: Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant pembrolizumab for organ-sparing treatment in patients with mismatch repair-deficient colorectal/colon cancer (stages I–III);…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Ismail Gögenur | Conditions: DMMR Colorectal Cancer, Colon Cancer Stage I | Phase 2 | Status: NOT_YET_RECRUITING